Lauter Empfehlungen wie hoch kann die Aktie steigen?? - 500 Beiträge pro Seite

[Euro_Million]

Wie hoch kann die Aktie steigen!?
Was ich gelesen habe hört sich ja sehr interessant an, aber ich denke das die Aktie eine sehr riskante Anlage ist!?
Ich möchte mal wissen was ihr dazu meint!?

Gruß Euro_Million

[Euro_Million]

Hat keiner diese Aktie??

[ustrading]

um welche Aktie geht es denn ... oder meinst du Aktien allgemein.

[Euro_Million]

Ich meine Id Biomedical WKN: 887103

[Euro_Million]

Hat jetzt All-Time-High!
Wow

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


09/05/2003 (16:11 ET) VOLUME(-): IDBE Volume 87% > 20-adsv, Stock -0.21% - Knobias



09/04/2003 (15:16 ET) VOLUME(+): IDBE Volume 66% > 20-adsv, Stock +3.62% - Knobias



09/04/2003 (12:02 ET) CONF: IDBE To Present At Biotech Newsmakers Conference @ 14:50 ET - Knobias



09/04/2003 (11:51 ET) BTC: JMP Provides Fall Preview of Biotech Industry - Knobias



09/04/2003 (10:06 ET) 52W HIGH: New 52-Wk High for IDBE @ $14.030 up1.59% - Knobias



08/29/2003 (09:12 ET) HCR: Jyske Banks Starts Healthcare Sector at Neutral - Knobias



08/28/2003 (15:01 ET) 6-K: IDBE Files Aug-25 PR Regarding 2nd Qtr Results - Knobias



08/28/2003 (14:58 ET) New 6-K just released for IDBE - Edgar



08/28/2003 (09:49 ET) 52W HIGH: New 52-Wk High for IDBE @ $13.900 up1.53% - Knobias



08/27/2003 (12:39 ET) Roth Ups IDBE`s Target on Future Pricing of FluINsure - Knobias



08/27/2003 (12:35 ET) RATING(1): Orion Initiates IDBE Rating @ Underweight - Knobias



08/27/2003 (12:27 ET) StreetInsider.com Inc.: Stock Movers of Note - Part 1 - M2 Communications



08/27/2003 (11:50 ET) StreetInsider Alert for IDBE - StreetInsider



08/27/2003 (10:09 ET) VOLUME(+): IDBE Volume 18% > 20-adsv, Stock +6.20% - Knobias



08/27/2003 (09:54 ET) 52W HIGH: New 52-Wk High for IDBE @ $13.220 up3.69% - Knobias



08/27/2003 (09:35 ET) StreetInsider Alert for IDBE - StreetInsider



08/27/2003 (09:05 ET) RATING(=): Roth Capital Reiterates IDBE Rating @ Buy - Knobias



08/26/2003 (16:17 ET) IDBE: Short Interest UP 35.3% to 1.2M in Aug 2003 - Knobias



08/26/2003 (16:17 ET) VOLUME(+): IDBE Volume 91% > 20-adsv, Stock +4.00% - Knobias



08/26/2003 (14:26 ET) 52W HIGH: New 52-Wk High for IDBE @ $13.000 up6.04% - Knobias



08/26/2003 (09:16 ET) RATING(=): Ryan Beck Reiterates IDBE Rating @ Outperform - Knobias



08/25/2003 (11:02 ET) 52W HIGH: New 52-Wk High for IDBE @ $12.950 up6.58% - Knobias



08/25/2003 (09:52 ET) IDBE Meets 2Q Est; (16c ) Vs (18c); No Guidance - Knobias



08/25/2003 (09:15 ET) ID Biomedical reports second quarter results - PR Newswire



08/25/2003 (09:15 ET) ID Biomedical reports second quarter results - Canada NewsWire


JS200

[js200]

Last Trade: 14.420 Change: 0.000 (+0.000%)
Previous Close: 14.420 Volume: 460,600
Bid: 14.000 Ask: 15.000
Today`s Open: 14.550 # of Trades: 1,086

Day High: 14.550 Day Low: 13.900
52 Week High: 14.590 52 week Low: 3.070
Market Cap: 437.66M Avg Daily Vol: 242,130
EPS: -0.44 PE Ratio: -32.773
Dividend: N/A Yield: N/A

JS200

[js200]

ID Biomedical reports second quarter results

TRADING SYMBOLS - NASDAQ - "IDBE", TSX - "IDB"

Monday , August 25, 2003 09:15 ET

VANCOUVER, Aug 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- ID Biomedical announced today that it recorded a net loss of $5.5 million or ($0.16) per share for the three month period ending June 30, 2003, compared to a net loss of $5.6 million or ($0.18) per share for the same three month period in 2002. The net loss for the six months ended June 30, 2003 was $9.6 million or ($0.29) per share, as compared to a net loss of $5.2 million or ($0.17) for the same period in 2002.

The Company had cash and short-term investments of $47.3 million at June 30, 2003 as compared to $23.8 million at December 31, 2002. At June 30, 2003, the Company had working capital of $44.4 million compared to $20.7 million at December 31, 2002.

During the second quarter of 2003, pursuant to a public offering, the Company issued 3,000,000 common shares at US $8.50 per common share for net proceeds of $32.4 million (net of offering expenses of $2.6 million). Net proceeds will be used to continue the clinical and manufacturing development of the Company`s subunit intranasal FluINsure(TM) vaccine and subunit StreptAvax(TM) vaccine, as well as for working capital requirements and other general corporate purposes.

The Company`s second quarter financial report will be available shortly at www.sedar.com. ID Biomedical will hold a live conference/web cast today, August 25, 2003 at 10:00 am PST; 1:00 pm EST. The Company will discuss second quarter financial results and provide an update on selected programs. To participate, please log on to http://www.newswire.ca/webcast/viewEventCNW.html?eventID(equal" target="_blank" rel="nofollow ugc noopener">http://www.newswire.ca/webcast/viewEventCNW.html?eventID(equal sign)619960 or call 416-405-9328. The conference call/web cast will be achieved until September 1, 2003. The number to access the archived conference call is 416- 695-5800, pass code 1470785.

About ID Biomedical

ID Biomedical is a biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome(TM) platform intranasal adjuvant/delivery technology.

ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases, as well as vaccines against biological warfare agents. The Company`s lead products in clinical development are the FluINsure(TM) intranasal influenza (flu) vaccine and the StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has several vaccines in preclinical development.

The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical`s expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical believes", "management believes" and similar language. All forward-looking statements are based on ID Biomedical`s current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties` intellectual property; iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products; vi) market acceptance of its technology and product; and (vii) the competitive environment and impact of technological change. There is no guarantee that the development path from Phase I to Phase II to Phase III and so on will be either linear or successful. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.


Contacts: ID Biomedical Corporation
Dean Linden
Manager, Corporate Communications
[phone]
www.idbiomedical.com


SOURCE ID Biomedical Corporation


CONTACT: ID Biomedical Corporation, Dean Linden, Manager, Corporate
Communications, 604-431-9314, www.idbiomedical.com;
To request a free copy of this organization`s annual report, please go to
http://www.newswire.ca and click on reports@cnw.
(IDB. IDBE)

http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: British Columbia
INDUSTRY KEYWORD: BIO
MTC
SUBJECT CODE: ERN
CCA


STOCK SYMBOLS: [(idb.)] [(idbe)]


JS200

[Euro_Million]

Datum: 11.06.03

Die Analysten von Ryan, Beck & Co bewerten in ihrer Analyse vom Dienstag, 10. Juni 2003 die Aktie von ID Biomedical Corp. neu mit dem Rating "Outperform". Das Kursziel für die Aktie liegt momentan bei 16 $.

Rating: Outperform
Analyst: Ryan, Beck & Co
Kursziel: 16

[Euro_Million]

Heute wieder All-Time High
Läuft echt gut!
Gruß Euro_Million